Matthew Blum is a Nephrology physician affiliated with University of Wisconsin–Madison. OpenAlex indexes 35 publications with 426 citations (h-index 10).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
600 Highland Ave
Madison, WI 537920020
Telephone
608-262-5420Provider last certified this registry record 30 Jan 2026.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
69.8%Angiotensin receptor blocker (ARB)16.9%Losartan Potassium63%Irbesartan23%Valsartan14%Part D<11 patientsCalcium channel blocker14%Amlodipine Besylate75%Nifedipine Er25%Part D<11 patients+ 7 more classes in this area
Metabolism & gastrointestinal
27.5%Vitamin D3 Analog14.4%Calcitriol100%Part D≥25 patientsSGLT2 inhibitor8.6%Jardiance70%Farxiga30%Part D<11 patients+ 2 more classes in this area
Genitourinary & hormones
2.7%alpha-Adrenergic Blocker2.7%Tamsulosin Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2026–2026 per NIH RePORTER. The latest:
- Multi-omics of fine particulate matter and chronic kidney disease
University of Wisconsin-Madison
FY2026$96,824K08DK142013
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Authors’ Reply: SGLT2 Inhibitors vs GLP-1 Receptor Agonists Type 2 Diabetes, the Kidney Conundrum
Clinical Journal of the American Society of Nephrology
2026 - Neighborhood Built Environment and Home Dialysis Utilization: Varying Patterns by Urbanicity-Dependent Patterns and Implications for Policy
American Journal of Kidney Diseases
2025 - A Drug-wide Association Study on Medications Associated With Cystatin C–Estimated GFR
American Journal of Kidney Diseases
2025 - A Target Trial Emulation Study of SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Combination Therapy in Preventing Kidney Failure in Type 2 Diabetes
Clinical Journal of the American Society of Nephrology
2025
Similar KOLs
Other experts from the same institution or the same specialty.
William Busse, MD
University of Wisconsin–Madison
David Andes, MD
University of Wisconsin–Madison
Neil Binkley, MD
University of Wisconsin–Madison
Robert Lemanske, MD
University of Wisconsin–Madison
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”